Reactivos e instrumentos para inmunología, biología celular y biología molecular.

Beauvericin [26048-05-5]

Imprimir

Referencia HY-N6739-10mg

embalaje : 10mg

Marca : MedChemExpress

Solicitar más información

Descripciòn

Beauvericin is a cyclohexapeptide Fusarium toxin with insecticidal, antibacterial, anticancer, antiviral and cytotoxic activities. Beauvericin causes cellular genotoxicity by producing DNA breaks, chromosomal aberrations and micronuclei, and inhibits the PI3K/AKT pathway to induce apoptosis, thereby inhibiting the growth of HCC. In addition, Beauvericin affects immune function by inhibiting lymphocyte proliferation and interfering with the differentiation process of human monocytes into macrophages^[1]^[2]^[3]^[4]^[5]^[6]^[7]^[8]^[9].

IC₅₀ & Target

ACAT

Cellular Effect

Cell Line	Type	Value	Description	References
HepG2	IC₅₀	1 μM Compound: 12	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 48 hr by CCK-8 assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 48 hr by CCK-8 assay	[PMID: 36288556]
Huh-7	IC₅₀	4.3 μM Compound: 12	Antiproliferative activity against human Huh-7 cells assessed as reduction in cell viability after 48 hr by CCK-8 assay Antiproliferative activity against human Huh-7 cells assessed as reduction in cell viability after 48 hr by CCK-8 assay	[PMID: 36288556]

In Vitro

Beauvericin (0-20 μM; 12, 24 and 36 h) has a strong antiproliferative activity against H22 hepatoma cells and promotes apoptosis of H22 hepatoma cells^[5].
Beauvericin (50 μM; 72 h) induces apoptosis in turkey peripheral mononuclear cells^[6].
Beauvericin (0.3-100 µM) reversibly inhibits L-type voltage-dependent Ca₂₊ current (I_Ca,L) in NG108-15 neuronal cells in a concentration-dependent manner with an IC₅₀ value of 4 µM^[7].
Beauvericin has IC₅₀ values of 1.0 µM, 2.9 µM, and 2.5 µM for immature dendritic cells, mature dendritic cells, and macrophages, respectively^[8].
Beauvericin (1.6 and 2.4 µM; 2 d) reduces CCR7 expression and increases IL-10 secretion in maturing dendritic cells^[8].
Beauvericin is a potent inhibitor of CYP3A1/2 in rat liver microsomes (IC₅₀=1.3 mM)^[9].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[5]

Cell Line:	H22 liver cancer cells
Concentration:	0, 1, 3, 5,10,15 and 20 µM
Incubation Time:	12、24 and 36 h
Result:	Inhibited the growth of H22 cells in a dose-dependent manner.

Western Blot Analysis^[5]

Cell Line:	H22 liver cancer cells
Concentration:	0, 1, 3, 5,10,15 and 20 µM
Incubation Time:	12、24 and 36 h
Result:	Upregulated the Bax/Bcl-2 ratio and the levels of cleaved caspase-9 and cleaved caspase-3, and downregulated the p-PI3K/PI3K ratio and p-AKT/AKT ratio.

In Vivo

Beauvericin (5 mg/kg; i.p.; after the first dosing cycle, observe for two days and continue the second dosing cycle) reduces tumor volume and increases necrosis in allogeneic transplant model mice^[3].
Beauvericin (3, 5, 7 mg/kg; i.p.; once a week for three weeks) can significantly inhibit the growth of H22 allogeneic transplant model mice and increase the levels of TNF-α and IL-2 in mice^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	BALB/c mice injected subcutaneously with mouse CT-26 colon cancer cells on the right side^[3]
Dosage:	5 mg/kg
Administration:	ntraperitoneal injection (i.p.)；The drug was administered on the third day after the injection of colon cancer cells and continued once a day for five days, then stopped for two days of observation, and continued on the tenth day after the injection of colon cancer cells, and continued once a day for four days.
Result:	Reduced the average tumor volume by 52.8 % and the average tumor weight by 60 %.

Animal Model:	Human cervical cancer KB-3-1 xenograft mouse model^[3]
Dosage:	5 mg/kg
Administration:	Intraperitoneal injection (i.p.)； The drug was administered once a day starting on the fifth day after cervical cancer injection for five days, followed by two days of observation. The drug was administered once a day starting on the twelfth day after cervical cancer cell injection for four days.
Result:	Reduced the average tumor volume by 31.3 % and the average tumor weight by 31.2 %.

Peso molecular

783.95

Fòrmula

C₄₅H₅₇N₃O₉

No. CAS

26048-05-5

Appearance

Solid

Color

White to off-white

SMILES

CN([C@H](C(O[C@](C(N([C@H](C(O[C@@H]1C(C)C)=O)CC2=CC=CC=C2)C)=O)(17)C(C)C)=O)CC3=CC=CC=C3)C([C@H](OC([C@@H](N(C1=O)C)CC4=CC=CC=C4)=O)C(C)C)=O

Structure Classification

Initial Source

Microorganisms

Fusarium proliferatum,F. semitectum, and F. subglutinans

Envío

Room temperature in continental US; may vary elsewhere.

Almacenamiento

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvente y solubilidad

In Vitro:

DMSO : 100 mg/mL (127.56 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.2756 mL	6.3780 mL	12.7559 mL
5 mM	0.2551 mL	1.2756 mL	2.5512 mL
10 mM	0.1276 mL	0.6378 mL	1.2756 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Calculadora de molaridad
Calculadora de dilución

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

Pureza y Documentación

Purity: 99.97%

Ficha de datos (287 KB) SDS (393 KB)

COA (261 KB) HNMR (224 KB) RP-HPLC (266 KB) LCMS (89 KB)

Instrucciones de manejo (2659 KB)

Referencias

[1]. Mallebrera B, et al. In vitro mechanisms of Beauvericin toxicity: A review[J]. Food and Chemical Toxicology, 2018, 111: 537-545. [Content Brief]

[2]. Wang Q, et al. Beauvericin, a bioactive compound produced by fungi: a short review[J]. Molecules, 2012, 17(3): 2367-2377. [Content Brief]

[3]. Heilos D, et al. The natural fungal metabolite beauvericin exerts anticancer activity in vivo: a pre-clinical pilot study[J]. Toxins, 2017, 9(9): 258. [Content Brief]

[4]. Maranghi F, et al. In vivo toxicity and genotoxicity of beauvericin and enniatins. Combined approach to study in vivo toxicity and genotoxicity of mycotoxins beauvericin (BEA) and enniatin B (ENNB)[J]. EFSA Supporting Publications, 2018, 15(5): 1406E.

[5]. Wang G, et al. Beauvericin exerts an anti-tumor effect on hepatocellular carcinoma by inducing PI3K/AKT-mediated apoptosis[J]. Archives of Biochemistry and Biophysics, 2023, 745: 109720. [Content Brief]

[6]. Dombrink-Kurtzman M A. Fumonisin and beauvericin induce apoptosis in turkey peripheral blood lymphocytes[J]. Mycopathologia, 2003, 156: 357-364. [Content Brief]

[7]. Wu S N, et al. Block of L-type Ca2+ current by beauvericin, a toxic cyclopeptide, in the NG108-15 neuronal cell line[J]. Chemical research in toxicology, 2002, 15(6): 854-860. [Content Brief]

[8]. Ficheux A S, et al. Effects of beauvericin, enniatin b and moniliformin on human dendritic cells and macrophages: An in vitro study[J]. Toxicon, 2013, 71: 1-10. [Content Brief]

[9]. Mei L, et al. An inhibition study of beauvericin on human and rat cytochrome P450 enzymes and its pharmacokinetics in rats[J]. Journal of enzyme inhibition and medicinal chemistry, 2009, 24(3): 753-762. [Content Brief]

Beauvericin [26048-05-5]

Referencia HY-N6739-10mg

Marca : MedChemExpress

Beauvericin Related Antibodies

Calculadora de molaridad

Calculadora de dilución